Latest News

Filters close
Newswise: FIRE-SCLC analysis: Largest ever study of first-line radiosurgery for brain metastases from small cell lung cancer
Released: 4-Jun-2020 6:10 PM EDT
FIRE-SCLC analysis: Largest ever study of first-line radiosurgery for brain metastases from small cell lung cancer
University of Colorado Cancer Center

The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit from whole-brain radiation compared with radiosurgery in patients with small cell lung cancer.

Newswise: Colorado tool, My-DST, may pick best multiple myeloma treatment
Released: 28-May-2020 12:10 PM EDT
Colorado tool, My-DST, may pick best multiple myeloma treatment
University of Colorado Cancer Center

University of Colorado Cancer Center team uses liquid biopsy to predict multiple myeloma drug resistance and sensitivity.

Newswise: Variations in side effect reporting makes drug safety unclear
Released: 28-Apr-2020 2:30 PM EDT
Variations in side effect reporting makes drug safety unclear
University of Colorado Cancer Center

University of Colorado Cancer Center study of early-phase clinical trials finds variations in reporting of drug side effects, potentially obscuring safety.

Newswise: Series of Rare Right-Colon Twists Highlights Need for Doctor Vigilance with New, Targeted Anti-Cancer Drugs
Released: 22-Apr-2020 10:05 AM EDT
Series of Rare Right-Colon Twists Highlights Need for Doctor Vigilance with New, Targeted Anti-Cancer Drugs
University of Colorado Cancer Center

Study: with smaller clinical trials, it may be up to doctors to notice rare drug side effects

Newswise: New mental health challenges for cancer patients during COVID-19
Released: 6-Apr-2020 12:05 PM EDT
New mental health challenges for cancer patients during COVID-19
University of Colorado Cancer Center

Benjamin Brewer, PsyD, is a University of Colorado Cancer Center investigator and health psychologist at the UCHealth University of Colorado Hospital Bone Marrow Transplant Program. Here CU Cancer Center talks with Dr. Brewer about his patients’ new worries and about how our health system is adapting to meet the mental health needs of cancer patients during COVID-19.

Newswise: Colorado study overturns ‘snapshot’ model of cell cycle in use since 1974
Released: 2-Apr-2020 3:05 PM EDT
Colorado study overturns ‘snapshot’ model of cell cycle in use since 1974
University of Colorado Cancer Center

Live, single-cell imaging shows that cells continuously integrate the influence of growth factors, not just during G1 phase of cell cycle, as previously thought.

Newswise: Experimental medication to prevent heart disease may treat chemo-resistant ovarian cancer
Released: 26-Mar-2020 11:55 AM EDT
Experimental medication to prevent heart disease may treat chemo-resistant ovarian cancer
University of Colorado Cancer Center

University of Colorado Cancer Center group shows CPT1A may be necessary for ovarian cancer spread, chemo-resistance. Moves toward clinical trial of CPT1A inhibitor, etomoxir, against chemo-resistant ovarian cancer.

Newswise: Study: Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG
Released: 25-Mar-2020 4:50 PM EDT
Study: Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG
University of Colorado Cancer Center

Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, "... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor," says lead researcher.

Newswise: Leading chloroquine scientists weigh in on drug as possible COVID-19 treatment
Released: 19-Mar-2020 4:35 PM EDT
Leading chloroquine scientists weigh in on drug as possible COVID-19 treatment
University of Colorado Cancer Center

“Two independent sources with the same scientific finding make you think it’s true,” says Jean Mulcahy-Levy, MD, investigator at CU Cancer Center and associate professor in the CU School of Medicine Department of Pediatrics.

Newswise: COVID-19 recommendations for patients receiving anti-cancer immunotherapies
Released: 19-Mar-2020 12:05 PM EDT
COVID-19 recommendations for patients receiving anti-cancer immunotherapies
University of Colorado Cancer Center

Could medicines that activate the immune system protect against COVID-19 infection?

Newswise: Post-diagnosis disparities drive poorer outcomes for pediatric Black and Hispanic brain cancer patients
Released: 12-Mar-2020 12:55 PM EDT
Post-diagnosis disparities drive poorer outcomes for pediatric Black and Hispanic brain cancer patients
University of Colorado Cancer Center

Of 1,881 patients under age 19 diagnosed with cancers of the brain and central nervous system between 2000 and 2015, 52 percent of White patients lived five years from diagnosis, whereas only 44 percent of African American patients and 45 percent of Hispanic patients reached a similar milestone.

Newswise: Less chemotherapy may have more benefit in rectal cancer
Released: 30-Jan-2020 10:55 AM EST
Less chemotherapy may have more benefit in rectal cancer
University of Colorado Cancer Center

University of Colorado Cancer Center study presented at the 2020 Gastrointestinal Cancers Symposium shows patients with locally advanced rectal cancer receiving lower-than-recommended doses of neoadjuvant chemotherapy in fact saw their tumors shrink more than patients receiving the full dose.

Newswise: Cancer study may accidentally help researchers create usable blood stem cells
Released: 16-Jan-2020 2:00 PM EST
Cancer study may accidentally help researchers create usable blood stem cells
University of Colorado Cancer Center

University of Colorado Cancer Center study shows healthy form of the leukemia-causing gene MLL may push pluripotent stem cells (which have proven difficult to use in human patients) to become durable hematopoietic stem cells (which are usable in patients, but have until now been impossible to make).

Newswise: University of Colorado Cancer Center named National Pancreas Foundation Center of Excellence
Released: 9-Jan-2020 8:05 AM EST
University of Colorado Cancer Center named National Pancreas Foundation Center of Excellence
University of Colorado Cancer Center

Due in part to advanced surgical techniques, more effective medicines, and a multidisciplinary approach to treating the disease, University of Colorado Cancer Center is able to operate on 30+ percent of pancreatic cancer patients, nearly double the national average.

Newswise: Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone
Released: 8-Jan-2020 12:15 PM EST
Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone
University of Colorado Cancer Center

Study shows Colorado drug SVC112 stops production of proteins that cancer stem cells need to survive and grow

Newswise: Tarloxotinib “very promising” against NRG1-fusion cancers
28-Mar-2019 11:05 AM EDT
Tarloxotinib “very promising” against NRG1-fusion cancers
University of Colorado Cancer Center

University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion cancers, in addition to the HER2/EGFR cancers for which the drug was originally designed.

Newswise: Treatment guidelines for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
Released: 12-Mar-2019 12:05 PM EDT
Treatment guidelines for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
University of Colorado Cancer Center

Article recently published in Aesthetic Surgery Journal formalizes the treatment strategy for this diagnosis, offering clear guidelines for plastic and oncologic surgeons.

Newswise: The sneaky way estrogen drives brain metastasis in non-estrogen-dependent breast cancers
Released: 7-Mar-2019 2:05 PM EST
The sneaky way estrogen drives brain metastasis in non-estrogen-dependent breast cancers
University of Colorado Cancer Center

University of Colorado Cancer Center study published in the journal Oncogene shows that while estrogen doesn’t directly affect triple-negative breast cancer cells, it can affect surrounding brain cells in ways that promote cancer cell migration and invasiveness.

Newswise: Leaders meet in Colorado to set research agenda for early-onset colorectal cancer
Released: 1-Feb-2019 12:05 PM EST
Leaders meet in Colorado to set research agenda for early-onset colorectal cancer
University of Colorado Cancer Center

While overall rates of colorectal cancer are down, the rate of young people getting the disease is up 22 percent over two decades. International leaders meet in Colorado to set the research agenda to figure out why.

Newswise: Breast cancer up to 5 times more likely to metastasize even 10 years after childbirth
Released: 16-Jan-2019 1:05 PM EST
Breast cancer up to 5 times more likely to metastasize even 10 years after childbirth
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that doctors may be underestimating the risk of and thus under-treating stage I and II breast cancers diagnosed within 10 years of childbirth.

Newswise: Cancer stem cells get energy from protein, and it’s proving to be their Achilles’ heel
Released: 12-Nov-2018 11:05 AM EST
Cancer stem cells get energy from protein, and it’s proving to be their Achilles’ heel
University of Colorado Cancer Center

CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Turning off protein metabolism kills these cells.

Newswise: New combination treatment flips the switch on melanoma cells
Released: 23-Oct-2018 12:05 PM EDT
New combination treatment flips the switch on melanoma cells
University of Colorado Cancer Center

Navitoclax plus A-1210477 not only killed melanoma cells, but also killed the melanoma initiating cells (aka cancer stem cells) that often resist therapy.

Newswise: Cancer Stem Cells Use “Normal” Genes in Abnormal Ways
Released: 12-Oct-2018 8:05 AM EDT
Cancer Stem Cells Use “Normal” Genes in Abnormal Ways
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."

Newswise: Cancer Hijacks the Microbiome to Glut Itself on Glucose
Released: 28-Sep-2018 11:05 AM EDT
Cancer Hijacks the Microbiome to Glut Itself on Glucose
University of Colorado Cancer Center

A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.

Newswise: Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
Released: 25-Sep-2018 8:05 AM EDT
Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
University of Colorado Cancer Center

Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.

Newswise: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer
24-Sep-2018 8:45 AM EDT
Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer
University of Colorado Cancer Center

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

Newswise: New Combination Treatment Targets Pre-Leukemia Stem Cells
Released: 12-Sep-2018 1:05 PM EDT
New Combination Treatment Targets Pre-Leukemia Stem Cells
University of Colorado Cancer Center

Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.

Newswise: Like Shark Attack and the Lottery, Unconscious Bias Influences Cancer Screening
Released: 17-Aug-2018 12:15 PM EDT
Like Shark Attack and the Lottery, Unconscious Bias Influences Cancer Screening
University of Colorado Cancer Center

Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.

Newswise: No single test identifies all ROS1+ lung cancer patients
Released: 8-Aug-2018 11:05 AM EDT
No single test identifies all ROS1+ lung cancer patients
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.

Newswise: Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
Released: 30-Jul-2018 10:05 AM EDT
Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
University of Colorado Cancer Center

Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.

Newswise: Brain Metastases Common and Difficult to Treat in ROS1 Lung Cancer
Released: 10-Jul-2018 12:05 PM EDT
Brain Metastases Common and Difficult to Treat in ROS1 Lung Cancer
University of Colorado Cancer Center

Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression.

Newswise: Updated ALEX Trial Results Show Alectinib Further Outpacing Crizotinib in Treatment Naive ALK+ NSCLC
Released: 3-Jun-2018 7:05 AM EDT
Updated ALEX Trial Results Show Alectinib Further Outpacing Crizotinib in Treatment Naive ALK+ NSCLC
University of Colorado Cancer Center

Dpdated data further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer.

Newswise: As Colorectal Cancer Rises in Young People, New Guidelines Recommend Screening Start at 45
Released: 30-May-2018 11:05 AM EDT
As Colorectal Cancer Rises in Young People, New Guidelines Recommend Screening Start at 45
University of Colorado Cancer Center

Study published today the journal Cancer recommends colorectal cancer screening start at age 45, five years younger than currently recommended for both men and women of all races and ethnicities.

Newswise: Ice Cream Funds Research Showing New Strategy Against Thyroid Cancer
Released: 21-May-2018 11:05 AM EDT
Ice Cream Funds Research Showing New Strategy Against Thyroid Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that stereotactic body radiation (SBRT) may be better against anaplastic thyroid cancer, and with fewer side effects.

Newswise: Largest-Ever Study of Thyroid Cancer Genetics Finds New Mutations, Suggests Immunotherapy
Released: 26-Apr-2018 1:05 PM EDT
Largest-Ever Study of Thyroid Cancer Genetics Finds New Mutations, Suggests Immunotherapy
University of Colorado Cancer Center

CU researchers mine data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers, showing genetic alterations, and "high mutation burden" that is an FDA-approved marker for immunotherapy.

Newswise: Global ROS1 Initiative Combines Patient Experience with Researcher Expertise to Target ROS1 Cancer Wherever It Grows
9-Apr-2018 12:00 PM EDT
Global ROS1 Initiative Combines Patient Experience with Researcher Expertise to Target ROS1 Cancer Wherever It Grows
University of Colorado Cancer Center

University of Colorado Cancer Center study presented at AACR 2018 describes new model for patient-researcher collaboration organized not around cancer type but around oncogene that causes many cancers

Newswise: Beyond PD-L1: Taking Away TIM3 and Tregs Stops Cancer Regrowth After Immunotherapy
9-Apr-2018 1:05 PM EDT
Beyond PD-L1: Taking Away TIM3 and Tregs Stops Cancer Regrowth After Immunotherapy
University of Colorado Cancer Center

CU Cancer Center study presented at AACR18 shows that TIM3 and/or increased regulatory T cells (Tregs) within a tumor may help cancers inactivate immune system killer T cells that would otherwise identify and attack the cancer.

Newswise: When Prostate Cancer Reaches Bone, Bone Cells May Drive Overall Growth of the Disease
9-Apr-2018 2:05 PM EDT
When Prostate Cancer Reaches Bone, Bone Cells May Drive Overall Growth of the Disease
University of Colorado Cancer Center

When prostate cancer metastasizes to bone, it can become especially dangerous – CU Cancer Center study at AACR18 hints at why: Cells involved in these bone metastases may release signals that drive the progression of the disease.

Newswise: How Do Melanoma Cells Survive Drug Treatment Long Enough to Acquire Drug Resistance?
9-Apr-2018 3:05 PM EDT
How Do Melanoma Cells Survive Drug Treatment Long Enough to Acquire Drug Resistance?
University of Colorado Cancer Center

University of Colorado Cancer Center study presented at AACR 2018 shows that even within three days of treatment, melanoma cells find a way to activate MEK – not with mutations, but with a more flexible and temporary way to allow these cancer cells to signal through the MAPK pathway even in the presence of BRAF inhibition.

Newswise: Cancer Comes Back All Jacked Up on Stem Cells
Released: 19-Mar-2018 4:00 PM EDT
Cancer Comes Back All Jacked Up on Stem Cells
University of Colorado Cancer Center

Three tumor samples collected over time from a single patient show how cancer evolves in response to treatment.

Newswise: Here's How Viruses Inactivate the Immune System, Causing Cancer
Released: 2-Mar-2018 8:05 AM EST
Here's How Viruses Inactivate the Immune System, Causing Cancer
University of Colorado Cancer Center

"The same mechanisms that viruses use to cause cancer may be key in combating tumors with immune-based therapies or in keeping cancer from developing in the first place," says Sharon Kuss-Duerkop, PhD.

Newswise: Expert Panel Issues New Guidelines for Lung Cancer Molecular Testing
Released: 30-Jan-2018 11:05 AM EST
Expert Panel Issues New Guidelines for Lung Cancer Molecular Testing
University of Colorado Cancer Center

Experts from three major organizations add ROS1 to list of tests matching lung cancer with targeted treatments.

Newswise: Study Suggests PD-1 Inhibitors Against Aggressive Pediatric Brain Cancer Subtype
Released: 29-Jan-2018 11:05 AM EST
Study Suggests PD-1 Inhibitors Against Aggressive Pediatric Brain Cancer Subtype
University of Colorado Cancer Center

A University of Colorado Cancer Center study published in the journal Pediatric Blood Cancers lays the scientific groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.

Newswise: Microbiome Predicts Blood Infections in Pediatric Cancer Patients
Released: 22-Jan-2018 11:05 AM EST
Microbiome Predicts Blood Infections in Pediatric Cancer Patients
University of Colorado Cancer Center

Patients who developed bloodstream infections had significantly reduced microbiome diversity than patients who remained free of infection.

Newswise: Treatment-Related Mortality of Surgery vs. Targeted Radiation in Early Lung Cancer Patients
Released: 19-Jan-2018 8:05 AM EST
Treatment-Related Mortality of Surgery vs. Targeted Radiation in Early Lung Cancer Patients
University of Colorado Cancer Center

Among patients older than 80 years, 3.9 percent receiving surgery passed away within the 30-day post-treatment window, compared with 0.9 percent of patients receiving focused radiation.

Newswise: Radiosurgery vs. Whole-Brain Radiation in Lung Cancer Patients with Multiple Brain Metastases
Released: 19-Dec-2017 11:05 AM EST
Radiosurgery vs. Whole-Brain Radiation in Lung Cancer Patients with Multiple Brain Metastases
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that radiosurgery may effectively treat brain metastases associated with certain types of lung cancer, even when the number of metastases exceeds established norms.

Released: 13-Dec-2017 11:05 AM EST
Even Smokers May Benefit From Targeted Lung Cancer Treatments
University of Colorado Cancer Center

When a targetable genetic alteration is present, matching the alteration with the appropriate targeted therapy is associated with a survival benefit of 1.5 years, regardless of smoking history.

Released: 30-Nov-2017 4:10 PM EST
Some Chemicals in Smoke May Be Even More Dangerous Than Previously Thought
University of Colorado Cancer Center

Though most “low molecular weight polycyclic aromatic hydrocarbons” (LMW PAHs) have not been shown to cause cancer alone, the study shows that in common combinations, these chemicals can help to spark the disease.

Released: 7-Nov-2017 11:05 AM EST
Study Finds a New Way to Shut Down Cancer Cells’ Ability to Consume Glucose
University of Colorado Cancer Center

Many cancers depend on glucose consumption for energy, but good pharmacological targets to stop cancers’ ability to uptake and metabolize glucose are missing. CU Cancer Center study finally identifies a way to restrict the ability of cancer to use glucose for energy.

Newswise: Important New Insights Into RECIST Criteria Measuring Cancer’s Response to Treatment
Released: 6-Nov-2017 4:35 PM EST
Important New Insights Into RECIST Criteria Measuring Cancer’s Response to Treatment
University of Colorado Cancer Center

CU Cancer Center study examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.


Showing results

150 of 189

close
1.19948